Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
|Motif Bio Conference Call and Webcast|
February 19, 2019
|Motif BioSciences Enters into Amendment Agreement with Hercules Capital|
February 18, 2019
|Motif Bio Receives Complete Response Letter from the FDA|
February 14, 2019